dm-3

DM3 (Maytansinoid DM3) is a maytansine mimic with disulfide or thiol groups, acting as a tubulin inhibitor and serving as the cytotoxic component in antibody-drug conjugates (ADCs).

DM3-SMe, a maytansine derivative and tubulin inhibitor, acts as the cytotoxic component in antibody-drug conjugates (ADCs). It can bind to antibodies through disulfide bonds or stable thioether bonds and demonstrates high in vitro cytotoxic activity with an IC50 of 0.0011.

OMDM-3 is a selective and metabolically stable anandamide cellular uptake (ACU) inhibitor with a Ki of 16.6 μM.

NCDM-32B, a novel potent and selective KDM4 inhibitor, impairs viability and transforms phenotypes of basal breast cancer.

DM-3411-d8 is a deuterated compound of DM-3411. DM-3411 has a CAS number of 913611-97-9. Brexpiprazole is a partial agonist of human 5-hydroxytryptamine (5-HT) 5-HT1A and dopamine D2 receptors.

LDN193189 (LDN-193189) (DM 3189) is a selective BMP signaling inhibitor, inhibiting the transcriptional activity of ALK2 and ALK3 (IC50s: 0.8/0.8/5.3/16.7 nM for ALK1/2/3/6).

KDM4-IN-2 is a potent and selective KDM4/KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.

Depiperazine-DM3189 inhibits the phosphorylation of SMAD 1/5/8 induced by bone morphogenetic protein 4 and can be used in biochemical experiments and drug synthesis.

BDM31343, an EthR inhibitor in Mycobacterium tuberculosis, enhances the antimicrobial activity of ethionamide with nanomolar potency, while improving solubility and metabolic stability.

Brexpiprazole S-oxide D8 (DM-3411 D8) is a deuterium-labeled Brexpiprazole S-oxide, the primary metabolite of Brexpiprazole, which is a partial agonist of human 5-HT1A and dopamine receptors (Kis: 0.12 nM and 0.3 nM).

Brexpiprazole S-oxide (DM-3411), a primary metabolite of Brexpiprazole, acts as a partial agonist of human 5-HT1A and dopamine receptors with Ki values of 0.12 nM and 0.3 nM, respectively.

RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.

BDM31827 is an EthR inhibitor.

LDN-193189 2HCl (DM-3189 2HCl) is a selective BMP signaling inhibitor that inhibits ALK1,ALK2,ALK3 and ALK6, showing IC50s of 0.8 nM, 0.8 nM, 5.3 nM, and 16.7 nM, respectively, in kinase assays.LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively. LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors ALK2 and ALK3 in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively, and was 200-fold more selective for BMP than for TGF-β.

LDN-193189 Tetrahydrochloride (DM-3189 Tetrahydrochloride) is a selective inhibitor of BMP type I receptors, inhibiting ALK2 and ALK3 (IC₅₀ = 5/30 nM), with weaker activity against ALK4, ALK5, and ALK7, and can be used for research into progressive osseous fibrodysplasia.

IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.

Rustmicin is a 14-membered macrolide identified as an inhibitor of plant pathogenic fungi.

CK37 controls the biological activity of Choline Kinase-α. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

BDM31369 is an activator of ethionamide.

P3FI-63 is a selective KDM3B inhibitor (IC50: 7 μM) with antitumor activity for the study of fusion-positive rhabdomyosarcoma and other transcriptionally addictive cancers.

Human IgG1(E356D/M358L/L234A/L235A)-kappa Isotype control is the isotype control for Human IgG1(E356D/M358L/L234A/L235A)-kappa antibody.

Human IgG1(E356D/M358L/L234A/L235A/F405L)-kappa Isotype control is the isotype control for Human IgG1(E356D/M358L/L234A/L235A/F405L)-kappa antibody.

Human IgG1(N297A/E356D/M358L)-kappa Isotype control is the isotype control for Human IgG1(N297A/E356D/M358L)-kappa antibody.

Human IgG1(K214R/E356D/M358L)-kappa Isotype control is the isotype control for Human IgG1(K214R/E356D/M358L)-kappa antibody.